94 related articles for article (PubMed ID: 19709164)
21. May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol.
Serra M; Pasello M; Manara MC; Scotlandi K; Ferrari S; Bertoni F; Mercuri M; Alvegard TA; Picci P; Bacci G; Smeland S
Int J Oncol; 2006 Dec; 29(6):1459-68. PubMed ID: 17088985
[TBL] [Abstract][Full Text] [Related]
22. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis.
Kyzas PA; Cunha IW; Ioannidis JP
Clin Cancer Res; 2005 Feb; 11(4):1434-40. PubMed ID: 15746043
[TBL] [Abstract][Full Text] [Related]
23. Tumor necrosis rate adjusted by tumor volume change is a better predictor of survival of localized osteosarcoma patients.
Kim MS; Lee SY; Cho WH; Song WS; Koh JS; Lee JA; Yoo JY; Jeon DG
Ann Surg Oncol; 2008 Mar; 15(3):906-14. PubMed ID: 18163171
[TBL] [Abstract][Full Text] [Related]
24. Survival after metastasis in osteosarcoma.
Sutow WW; Herson J; Perez C
Natl Cancer Inst Monogr; 1981 Apr; (56):227-31. PubMed ID: 6946292
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of immunohistochemical expression of ezrin in non-metastatic high-grade osteosarcoma.
Ferrari S; Zanella L; Alberghini M; Palmerini E; Staals E; Bacchini P
Pediatr Blood Cancer; 2008 Apr; 50(4):752-6. PubMed ID: 17886294
[TBL] [Abstract][Full Text] [Related]
26. Ki-67: a proliferative marker that may predict pulmonary metastases and mortality of primary osteosarcoma.
Hernández-Rodríguez NA; Correa E; Sotelo R; Contreras-Paredes A; Gomez-Ruiz C; Green L; Mohar A
Cancer Detect Prev; 2001; 25(2):210-5. PubMed ID: 11341357
[TBL] [Abstract][Full Text] [Related]
27. Prognostic effect of pathologic fracture in localized osteosarcoma: a cohort/case controlled study at a single institute.
Kim MS; Lee SY; Lee TR; Cho WH; Song WS; Cho SH; Lee JA; Yoo JY; Jung ST; Jeon DG
J Surg Oncol; 2009 Sep; 100(3):233-9. PubMed ID: 19294672
[TBL] [Abstract][Full Text] [Related]
28. Role of Her-2/neu overexpression and clinical determinants of early mortality in glioblastoma multiforme.
Koka V; Potti A; Forseen SE; Pervez H; Fraiman GN; Koch M; Levitt R
Am J Clin Oncol; 2003 Aug; 26(4):332-5. PubMed ID: 12902879
[TBL] [Abstract][Full Text] [Related]
29. Tenascin-C as a prognostic biomarker in osteosarcoma?
Xiong W; Niu PY; Zhu WT; Chen J
Chin Med J (Engl); 2009 Nov; 122(22):2737-43. PubMed ID: 19951606
[TBL] [Abstract][Full Text] [Related]
30. Expression of C-erbB-2/HER-2 in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous blood stem cell support.
Bewick M; Chadderton T; Conlon M; Lafrenie R; Morris D; Stewart D; Glück S
Bone Marrow Transplant; 1999 Aug; 24(4):377-84. PubMed ID: 10467326
[TBL] [Abstract][Full Text] [Related]
31. Effect of HER-2/neu overexpression on chemoresistance and prognosis in ovarian carcinoma.
Sasaki N; Kudoh K; Kita T; Tsuda H; Furuya K; Kikuchi Y
J Obstet Gynaecol Res; 2007 Feb; 33(1):17-23. PubMed ID: 17212661
[TBL] [Abstract][Full Text] [Related]
32. Human epidermal growth factor receptor-2 family in colorectal adenocarcinoma: correlation with survival and clinicopathological findings.
Molaei M; Pejhan S; Nayer BN; Moradi A; Ghiasi S; Zali MR
Eur J Gastroenterol Hepatol; 2009 Mar; 21(3):289-93. PubMed ID: 19279475
[TBL] [Abstract][Full Text] [Related]
33. Expression of heat shock proteins in osteosarcomas.
Moon A; Bacchini P; Bertoni F; Olvi LG; Santini-Araujo E; Kim YW; Park YK
Pathology; 2010; 42(5):421-5. PubMed ID: 20632817
[TBL] [Abstract][Full Text] [Related]
34. Prognostic contribution of the HER-2 oncogene overexpression to the Nottingham Prognostic Index in breast cancer.
Suen D; Chow LW
Biomed Pharmacother; 2006 Jul; 60(6):293-7. PubMed ID: 16828252
[TBL] [Abstract][Full Text] [Related]
35. COPS3 amplification and clinical outcome in osteosarcoma.
Yan T; Wunder JS; Gokgoz N; Gill M; Eskandarian S; Parkes RK; Bull SB; Bell RS; Andrulis IL
Cancer; 2007 May; 109(9):1870-6. PubMed ID: 17366602
[TBL] [Abstract][Full Text] [Related]
36. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols.
Kager L; Zoubek A; Pötschger U; Kastner U; Flege S; Kempf-Bielack B; Branscheid D; Kotz R; Salzer-Kuntschik M; Winkelmann W; Jundt G; Kabisch H; Reichardt P; Jürgens H; Gadner H; Bielack SS;
J Clin Oncol; 2003 May; 21(10):2011-8. PubMed ID: 12743156
[TBL] [Abstract][Full Text] [Related]
37. [Surgical treatment of pulmonary metastases of osteosarcoma. Apropos of 206 operated cases].
Briccoli A; Ferrari S; Picci P; Mercuri M; Bacci G; Guernelli N
Ann Chir; 1999; 53(3):207-14. PubMed ID: 10339862
[TBL] [Abstract][Full Text] [Related]
38. Expression of HER2/erbB-2 correlates with survival in osteosarcoma.
Gorlick R; Huvos AG; Heller G; Aledo A; Beardsley GP; Healey JH; Meyers PA
J Clin Oncol; 1999 Sep; 17(9):2781-8. PubMed ID: 10561353
[TBL] [Abstract][Full Text] [Related]
39. Survival in osteosarcoma in relation to tumor size and location.
Broström LA; Strander H; Nilsonne U
Clin Orthop Relat Res; 1982 Jul; (167):250-4. PubMed ID: 6954021
[TBL] [Abstract][Full Text] [Related]
40. Expression of molecular markers in the tumor and survival prognosis in osteosarcoma.
Boulytcheva IV; Soloviev YN; Kushlinskii NE; Mahson AN
Bull Exp Biol Med; 2010 Dec; 150(2):237-42. PubMed ID: 21240382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
